Clinical trial KEYNOTE-756
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Merck |
| EudraCT Identifier | 2017-004869-27 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03725059 |
| Inclusion criteria | ER+/HER2-. Stage III. cT1c-2 (>2cm). N1-2 or T3-4N0-2. Neoadjuvant |
| Last update |